Daily BriefsThematic (Sector/Industry)

Daily Brief Thematic (Sector/Industry): Ohayo Japan|Equities Cruise on No Recession Narrative; NUGGET: JAL(9201) A Double Winner and more

In today’s briefing:

  • Ohayo Japan|Equities Cruise on No Recession Narrative; NUGGET: JAL(9201) A Double Winner
  • [Blue Lotus EV Sector Update]: All Solid-State Battery Unlikely to Disrupt EV Market
  • China TMT Update-LI AUTO/Akeso/BEKE-Delay Chongqing Plant/Trial of Cadonilimab BsAb/New Home Sales
  • US PPI: Tailwinds from Transportation Price Collapse Set to Subside in H2 2023
  • The Highlights – Cannabis News for the Week Ending July 14, 2023
  • WRKR Limited – Super Opportunities Ahead


Ohayo Japan|Equities Cruise on No Recession Narrative; NUGGET: JAL(9201) A Double Winner

By Mark Chadwick

  • OVERSEAS.  SPX hit 52W highs as Yellen sees no US Recession;  Rates fall on “inflation behind us” narrative; Global HF unwind bearish US positions; EV WARS as Ford Slashes prices. 
  • JAPAN.  NKY Futures -0.2% vs Cash; USDJPY 138.7%; Japan Back after Marine Day Holidays to lower US rates, stronger yen, Weaker China, and Tech bid; Blackrock lifts Japan stock outlook
  • NUGGET.  JAL(9201) Double Winner(Margins+Emmissions) with Fleet Upgrade. Share price has run, but strong tailwinds on demand and operational efficiency. Watch for pullback to pick up.

[Blue Lotus EV Sector Update]: All Solid-State Battery Unlikely to Disrupt EV Market

By Shawn Yang

  • In early July, Toyota announced a breakthrough in all-solid-state-battery (ASSB) delivering 745 miles per charge and <10-minute charging time. 
  • Currently lithium-ion battery (LIB) can reach 500 miles and 25 minutes; We, however, believe the migration of LIB to ASSB will be a continuous process. 
  • ASSB is expensive to manufacture. Further, mineral reliance on China is unlikely to lessen.

China TMT Update-LI AUTO/Akeso/BEKE-Delay Chongqing Plant/Trial of Cadonilimab BsAb/New Home Sales

By Shawn Yang

  • LI: Li Auto said to postpone the construction of Chongqing plant (-)
  • Akeso started Phase III head-to-head trial of its Cadonilimab BsAb against BeiGene’s Tislelizumab mAb for first line treatment of NSCLC(/)
  • KE Holdings: New home sales remain weak in June, and existing home price trended down for two months, expecting more supportive policy on demand side of property market.

US PPI: Tailwinds from Transportation Price Collapse Set to Subside in H2 2023

By Daniel Hellberg

  • US PPI has steadily eased over the past 15 months, and lower transportation costs have helped
  • US long-distance trucking and international air freight costs have fallen dramatically from the peak, but ocean freight has surprisingly remained close to peak levels
  • We believe falling transportation costs are unlikely to provide “tailwinds” for much longer

The Highlights – Cannabis News for the Week Ending July 14, 2023

By Water Tower Research

  • Global equities rallied this week on softer CPI and PPI reports.

  • One year ago, CPI was 9.1%, compared to last week’s 3.0%, showing the Fed’s action has slowed inflation.

  • This puts less pressure on the Fed to continue raising rates.


WRKR Limited – Super Opportunities Ahead

By Research as a Service (RaaS)

  • Wrkr Ltd (ASX:WRK) offers compliance solutions for Australian superannuation contributions and payroll including member onboarding, clearing, messaging and employee validation.
  • WRK’s product solutions need to address and comply with a range of government regulations that continue to evolve, with examples being Single Touch Payroll 2.0, Your Future Your Super, Pay Day Super, Rollovers 3.0, and the Security of Critical Infrastructure.
  • Such regulations provide somewhat of a moat for competitors looking to enter the space and strong customer retention once secured. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars